Chargement en cours...
Imatinib induced severe skin reactions and neutropenia in a patient with gastrointestinal stromal tumor
BACKGROUND: Imatinib mesylate has been used for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST). The current recommended dose of imatinib is 400 mg/day that is increased to 800 mg/day in cases with disease progression. However, imatinib can be associated with diver...
Enregistré dans:
| Auteurs principaux: | , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BioMed Central
2010
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2936326/ https://ncbi.nlm.nih.gov/pubmed/20718969 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-10-438 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|